Genovis Establishes Subsidiary In The U.S.

The subsidiary will sell all of the parent company's products on the North American market, which today represents 60 percent of Genovis’ total sales. Customers include the major pharmaceutical companies, which use the products to screen new drug substances and for quality control in development and production of new antibody-based drugs. The subsidiary will be headed by John M. Lindsay and Philip Onigman, both of whom have extensive experience in sales and business development in the Life Science market.

“We are now pursuing our strategy and establishing a presence with direct sales in our largest market. Proximity to customers, accessible and skilled support, a local warehouse and efficient deliveries are important cornerstones of our offering. We are very pleased to have John Lindsay and Philip Onigman join us in our US operations. Both are well-established and have extensive experience in our industry. We look forward to an exciting and successful collaboration,” says Sarah Fredriksson, CEO Genovis

John M Lindsay

John began his career at Millipore Corporation and quickly advanced to executive vice president and business area manager of several divisions of the company. In 2000 John founded SciPartners, with the objective of building a platform for development of early European companies and brands in North America. John’s focus is the Life Science market, and over the past 14 years he has successfully built up sales and marketing that led to rapid growth and increased revenues for many companies.

Philip Onigman

Philip is principal and founder of Grand Street Consulting, specializing in marketing for the Biotechnology Industry. Philip earned a BS in Microbilogy/Biochemistry from the University of New Hampshire, and worked in clinical and research laboratories at Massachusetts General Hospital and Tufts Medical Center. Philip has served in commercialization and business development roles including Technical Support, Market Development, Product Management and Sales at Millipore, Lionbridge Technologies, GTC BioTherapeutics and AdvanDx.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235


Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Help employers find you! Check out all the jobs and post your resume.

Back to news